Bacterial Infection Amongst Multiple Myeloma Patients Treated With Bortezomib- Based Induction Therapy: Real-World Experience in an Asian Cancer Center
In an evaluation of 108 newly-diagnosed myeloma patients treated with bortezomib-based induction therapy with adequate access to healthcare facilities and timely supportive care, without routine fluoroquinolone prophylaxis, but with routine Pneumocystis Carinii prophylaxis (mostly with trimethoprim-sulfamethoxazole), the proportion of patients with significant bacterial infection is low. We also showed that low absolute neutrophil count, ISS stage, and renal impairment are associated with increased risk of febrile episodes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Cinnie Yentia Soekojo, Jia Zhen Low, Jaslyn Oh, Melissa Ooi, Sanjay De Mel, Wee Joo Chng Tags: Original Study Source Type: research
More News: Bactrim | Cancer | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Study | Sulfamethoxazole | Trimethoprim | Velcade